abemaciclib,ribociclib,palbociclib
novartis,pfizer,eli lilly
['maintain trial', 'abemaciclib', 'ribociclib', 'palbociclib']
 maintain trial: use of ribociclib plus endocrine therapy after progression on prior cdk4/6i 86% had prior palbociclib; 10% ribociclib; 4% abemaciclib 5.3 vs 2.7 mo 0.57 no benefit in pts with esr1 mutation! very important data! #asco22 
Physician Scientist/Breast Oncology specialist @mdandersonnews - ????????Views are mine; Retweet ? endorsement; Scientific advisory board member @LobularBCA